Kidneys
are among the most crucial organs of the human body. Their role in
regulating blood pressure and serving homeostatic functions is
critical in maintaining the balance of nutrients and toxins in the
body. Kidneys serve as natural blood filters, removing the
water-soluble wastes and reabsorbing the essential elements from the
blood. Since they play such a crucial role, kidneys require constant
regeneration of dead nephrons and proper blood circulation to
maintain healthy cell growth, due to which, they are susceptible to
metastasis and cancerous tumors.
Browse
Kidney Cancer Drugs Market Report with Full TOC at
http://www.transparencymarketresearch.com/kidney-cancer-drugs-market.html
Renal
cell carcinoma, the most common type of kidney cancer, is among the
toughest cancers to treat, especially in the advanced stages. Until
1980’s, the treatment of kidney cancer included surgical removal of
the kidneys. The treatment later progressed to laparoscopic removal
of the tumor-affected part of the kidneys, significantly increasing
the survival rate and patient comfort. Drugs are usually given to
stage four advanced renal cell carcinoma patients with disease
progression. Various forms of cancer treatment mechanism have been
implemented among the presently approved drugs for kidney cancer;
these include, VEGF (Vascular Endothelial Growth Factor) inhibitor,
angiogenesis inhibitor, cytokine therapy, and immune modulation
therapy to name a few.
This
research report provides a detailed analysis of the global kidney
cancer drugs market and helps in understanding the various driving
factors of this market. The market overview section provides analysis
of the market dynamics and trends such as drivers, restraints, and
opportunities that influence the current nature of the market. The
section also forecasts the future scenario of the market. The
executive summary gives detailed insights about the report and the
market in general. It also contains a market snapshot, which provides
a glimpse into the current scenario of the global kidney cancer drugs
market. Event impact analysis and other market dynamics tools such as
market attractiveness analysis, regulatory framework analysis, and
market share analysis have also been explained in the market overview
section of the report, in order to deliver a thorough analysis of the
overall competitive scenario in the global kidney cancer drugs
market.
Request
for customization of this report
http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=537
The
global kidney cancer drugs market is segmented on the basis of major
branded drugs produced and geography. By major branded drugs, the
market is further segmented into the major brands approved for the
indication of renal cell carcinoma such as Afinitor (Everolimus),
Avastin (Bevacizumab), Inlyta (Axitinib), Nexavar (Sorafenib),
Proleukin (Aldesleukin/Interleukin-2), Sutent (Sunitinib), Torisel
(Temsirolimus), and Votrient (Pazopanib). The report also includes
pipeline analysis of the most potential drugs, which are currently in
phase 2 and phase 3 trials for renal cell carcinoma indication.
Considering 2013 as the base year for estimating the market size and
2012 as the historical year, the market size estimations for the
period from 2012 to 2020 have been provided for each of the major
branded drugs mentioned above in terms of USD million. The CAGR (%)
of each market segment for the forecast period between 2012 to 2016
and 2016 to 2020 has also been provided along with market size
estimations.
Geographically,
the global kidney cancer drugs market has been segmented into four
major regions: North America, Europe, Asia Pacific, and Rest of World
(RoW), Russia being included in the RoW region. The market size
estimations for the period between 2012 and 2020 and market forecast
for the period 2014 - 2020 have been provided for each of these
regions by revenue in terms of USD million along with the CAGR for
the forecast period 2014 to 2020. This study further offers market
recommendations for market players of the global kidney cancer drugs
market, which include factors that may play a critical role in
enhancing or boosting the market share of companies in the near
future. The report also advices measures that need to be considered
to achieve success for kidney cancer drug manufacturers and marketers
globally.
The
report concludes with company profiles, which include key information
about the major players actively participating in the kidney cancer
drugs market. The report profiles the market players in terms of
company overview, financial overview, business strategy, recent
developments, and product portfolio. The companies featured in this
report have exclusive patent rights to the following major branded
drugs: Novartis AG., F. Hoffman-La Roche., Pfizer, Inc., Bayer Pharma
AG., and GlaxoSmithKline, plc.
The
global kidney cancer drugs market is segmented as follows:
Kidney
Cancer Drugs Market, by Major Branded Drugs
- Sutent (Sunitinib)
- Nexavar (Sorafenib)
- Afinitor (Everolimus)
- Votrient (Pazopanib)
- Inlyta (Axitinib)
- Avastin (Bevacizumab)
- Torisel (Temsirolimus)
- Proleukin (Aldesleukin)
Kidney
Cancer Drugs Market, by Geography
- North America
- Europe
- Asia Pacific
- Rest of the World (RoW)
Browse all
Pharmaceutical Market Research Reports@
http://www.transparencymarketresearch.com/pharmaceutical-market-reports-1.html
About Us
Transparency Market
Research is a global market intelligence company, providing global
business information reports and services. Our exclusive blend of
quantitative forecasting and trends analysis provides forward-looking
insight for thousands of decision makers. We are privileged with
highly experienced team of Analysts, Researchers, and Consultants,
who use proprietary data sources and various tools and techniques to
gather, and analyze information.
Our data repository
is continuously updated and revised by a team of research experts, so
that it always reflects the latest trends and information. With a
broad research and analysis capability, Transparency Market Research
employs rigorous primary and secondary research techniques in
developing distinctive data sets and research material for business
reports.
Contact
Nachiket
90 State Street,
Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll
Free: 866-552-3453
No comments:
Post a Comment